Amgen Inc. (NASDAQ:AMGN): Closing price $111.93
On Monday, Amgen reported additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC, or IV melanoma versus granulocyte-macrophage colony-stimulating factor (GM-CSF). Results of the study’s key secondary endpoints will be presented during a poster session at the 17th ECCO — 38th ESMO — 32nd ESTRO European Cancer Congress in Amsterdam.
New data presented include investigator assessments of response: the durable response rate stood at 19 percent with talimogene laherparepvec as compared with one percent for the GM-CSF arm, and the objective response rate was 31 percent versus six percent in the GM-CSF arm.
ImmunoGen, Inc. (NASDAQ:IMGN): Closing price $17.02
ImmunoGen has announced the results from Roche’s TH3RESA Phase III trial being presented Monday at the European Cancer Congress in Amsterdam. The data were accepted as late-breaking data and also included in the Congress official press program. Kadcyla was found to significantly extend duration of progression-free survival compared to treatment with physicians choice (median 6.2months vs. 3.3 months, respectively) and lowered the risk of disease or death by 47 percent. ImmunoGen is a biotech firm that develops novel anticancer therapeutics employing its antibody-drug conjugate technology.
Clovis Oncology Inc. (NASDAQ:CLVS): Closing price $60.78
Clovis announced Monday updated results from an ongoing Phase I/II monotherapy evaluation of rucaparib, its oral, potent, small molecule poly (ADP-ribose) polymerase inhibitor being developed for the treatment of ovarian cancer. Data from the Phase I dose-escalation portion of this Phase I/II study are being presented at a poster session during the European Cancer Congress 2013 in Amsterdam. President and Chief Executive of Clovis Oncology Patrick J. Mahaffy said that these data show that rucaparib is both well-tolerated and predictably absorbed, and gives meaningful clinical benefit to certain ovarian cancer patients.
CytRx Corp. (NASDAQ:CYTR): Closing price $3.23
On Monday, CytRx reported compelling preliminary data from its global Phase 2b soft tissue sarcoma trial, showing that patients treated with aldoxorubicin experienced a significantly higher Overall Response Rate of 22 percent versus those administered the widely-used chemotherapeutic agent doxorubicin with an ORR of zero percent. CytRx is a biopharmaceutical research and development firm specializing in oncology.